Stockscreener 앱 받기
0.429
0.28%
-0.0012
시간 외 거래:
.42
-0.009
-2.10%
Femasys Inc 주식(FEMY)의 최신 뉴스
Weekly Trades: Is Femasys Inc stock undervalued right now2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale - MSN
Market Rankings: Can Femasys Inc sustain its profitabilityBond Market & Fast Moving Stock Trade Plans - baoquankhu1.vn
Femasys (NASDAQ: FEMY) targets reverse split and dilutive note, warrant share issuances - Stock Titan
Can Femasys Inc grow without external funding2026 Closing Moves & Advanced Technical Signal Analysis - baoquankhu1.vn
Femasys appoints John Canning as COO - MSN
Femasys Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Femasys names John Canning as chief operating officer By Investing.com - Investing.com South Africa
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
FEMASYS (FEMY) COO awarded 150,000 stock options at $0.38 exercise price - Stock Titan
Femasys (FEMY) COO John Canning discloses ownership of 30,000 shares - Stock Titan
Femasys Names John Canning as New Chief Operating Officer - TipRanks
Femasys Inc. Appoints John Canning as Chief Operating Officer, Effective March 30, 2026 - marketscreener.com
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth - bitget.com
Femasys names John Canning as chief operating officer - Investing.com
Femasys names John Canning as Chief Operating Officer - TradingView
Veteran MedTech leader John Canning joins Femasys (NASDAQ: FEMY) as COO - Stock Titan
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - The Manila Times
Femasys earnings beat by $0.12, revenue fell short of estimates - ca.investing.com
Femasys 2025 10-K: Revenue $2.29M, Net loss per share $(0.47) - TradingView — Track All Markets
Femasys (NASDAQ: FEMY) advances FemBloc and FemaSeed women’s health platform - Stock Titan
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Femasys 2025 sales jump on FemBloc demand - TradingView — Track All Markets
Femasys (NASDAQ: FEMY) details 2025 results and FemBloc FINALE trial - Stock Titan
Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
John Charles Canning Net Worth (2026) - GuruFocus
FEMY Should I Buy - Intellectia AI
Femasys (FEMY) price target decreased by 17.74% to 4.34 - MSN
Femasys (FEMY) CFO receives 34,122 Series D-1 warrants at $0.58 - Stock Titan
Femasys (NASDAQ: FEMY) director awarded 34,122 Series D-1 warrants - Stock Titan
Board seeks reverse split, Nasdaq‑rule approval for issuances (FEMY) - Stock Titan
Femasys (NASDAQ: FEMY) director discloses notes, warrants and share stake - Stock Titan
Femasys Inc. Enters Omnibus Amendment and Issues Series D-1 Warrants – SEC 8-K Filing March 2026 - Minichart
Femasys amends warrants and notes, appoints new director to board By Investing.com - Investing.com India
Femasys amends warrants and notes, appoints new director to board - Investing.com
Femasys (NASDAQ: FEMY) director receives stock options for 35,200 shares - Stock Titan
Femasys Amends Financing Terms and Issues New Warrants - TipRanks
Femasys enters omnibus amendment and consent agreement on March 19, 2026SEC filing - MarketScreener
Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026SEC Filing - TradingView
Femasys Amends Notes and Warrants; Issues 16.38M New Warrants at $0.58 to Holders - TradingView
Femasys (FEMY) grants 16.4M Series D-1 warrants and appoints new independent director - Stock Titan
Femasys Inc. announced that it has received $12 million in funding - marketscreener.com
Femasys appoints anesthesiologist to board of directors By Investing.com - Investing.com South Africa
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
Femasys (NASDAQ: FEMY) director Joshua Silverman files neutral Form 4 - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
Femasys Inc. Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - marketscreener.com
Femasys appoints anesthesiologist to board of directors - Investing.com
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - Bitget
Femasys Inc. Appoints Kenneth D. Eichenbaum, M.D., M.S.E., to Board of Directors - Quiver Quantitative
Femasys appoints Dr. Kenneth D. Eichenbaum to board of directors - marketscreener.com
0.06%
1.84%
자본화:
|
볼륨(24시간):